Xlife Sciences AG's book value per share for the quarter that ended in Dec. 2025 was CHF49.68.
During the past 12 months, Xlife Sciences AG's average Book Value Per Share Growth Rate was -6.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 3.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Xlife Sciences AG was 21.40% per year. The lowest was 3.70% per year. And the median was 15.30% per year.
Xlife Sciences AG's current price is CHF19.40. Its book value per share for the quarter that ended in Dec. 2025 was CHF49.68. Hence, today's PB Ratio of Xlife Sciences AG is 0.39.
During the past 8 years, the highest P/B Ratio of Xlife Sciences AG was 1.25. The lowest was 0.33. And the median was 0.70.
Xlife Sciences AG (XSWX:XLS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Xlife Sciences AG Book Value per Share Related Terms
Xlife Sciences AG Book Value per Share Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Book Value per Share Comparison
For the Biotechnology subindustry, Xlife Sciences AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's PB Ratio distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Book Value per Share of CHF49.68 mean?
Xlife Sciences AG (XSWX:XLS) has a Book Value per Share of CHF49.68 as of Dec. 2025. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Book Value per Share too high?
Xlife Sciences AG's current Book Value per Share is CHF49.68. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Book Value per Share compare to VRTX and REGN?
Xlife Sciences AG's Book Value per Share of CHF49.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Book Value per Share is CHF49.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.29, compared to a current price of CHF19.40 — trading 166.1% above its estimated fair value. The current Book Value per Share is CHF49.68. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Book Value per Share is CHF49.68 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF19.40 is trading 166.1% above its estimated GF Value™ of CHF7.29.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Book Value per Share: CHF49.68
GF Value™: CHF7.29 vs. price of CHF19.40 (166.1% above fair value)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
